In the 19th century, the term "depression" (deprimere: to press down) became in use and appeared in medical dictionaries to refer to a physiological and metaphorical lowering of emotional function. The newer concept abandoned the associations of the ancient Greeks and through the 19th century, became more associated with women.
Depression Today

Most experts agree on the following:
A depressive disorder is a syndrome that reflects a sad and/or irritable mood exceeding normal sadness or grief.
Depression disorders today are a huge public-health problem: It affects about 10% of adults, 8% of teens, 2% of preteens. They involve huge amounts of direct costs (treatment) and indirect costs (loss of productivity) They can increase risks for developing coronary artery disease, HIV, asthma, . . .
Causes of Depression
Depression is not something you can just "snap out".
It is caused by an imbalance of brain chemicals that carry signals in your brain and nerves.
These chemicals are called neurotransmitters.
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Not a lot is known about the effects of neurotransmitters This is due to the fact that they are difficult to study:
Neurotransmitters: are present in very small quantities in certain locations within the brain disappear very quickly once used and can therefore not be measured directly 
Goals and Objectives of the Current
Research
Can we identify genomic biomarkers, based on gene and metabolite expressions, for depression? Such biomarkers could be applied to develop and guide more efficient drug development and testing programs.
Objective 1: select and evaluate a set of genes and metabolites as possible biomarkers for depression as measured by the HAMD score
Objective 2: construct a joint biomarker that combines relevant information from a subset of genes or metabolites, to predict the HAMD score. Gene-specific Joint Model:
fitted for each gene separately
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Joint Model for Gene Expression and HAMD
Adjusted association (Buyse and Molenberghs 1998):
ρ j can be equal to 1 even if the gene is not differentially expressed; to select genes which can predict the response, there is no need for the gene to be differentially expressed.
Information-theory Approach
How to quantify association if we move away from normal distribution?
Alonso et al. (2005, 2007) : Likelihood Reduction Factor:
where G 2 denotes the likelihood ratio statistics to compare models:
with γ j the gene-specific effect upon the outcome.
Four-Variate Model
Instead of taking changes from baseline, the association can also be quantified using the pre and post measurements per subject for gene/metabolite expression and HAMD:
Measure of Association (gene-specific):
Results for top 5 genes 
Joint Biomarker
How to combine information about expression levels from all genes/metabolites in the array into one variable?
Supervised Principal Component
Analysis (SPCA)
Basic Assumption: There exists a latent variable U(X) that is associated with the response variable Y.
Number of genes larger than number of observations, therefore: data reduction
Reduce dimension of X giving most weight to those genes that have the strongest relationship with the response
Supervised Principal Component
Analysis (SPCA)
Steps:
1. Fit one of the gene-specific models and estimate the association measure 2. Form a reduced expression matrix consisting of only those genes whose gene-specific association measure exceeds a threshold level (or top k)
3. Let X R be the reduced matrix.
4. Use the first principal component in a regression model to predict the response.
5. Assess the association using the methods described above 
Supervised Partial Least Squares (SPLS)
4. Fit a partial least squares regression and take the first factor, U (R) (PLS selects components of X that are also relevant to Y ).
5. Select the genes with the largest influence on the resulting latent factor and use them to construct the joint biomarker 6. Assess the association using the methods described above 
Results
A test of significance for the joint biomarker based on the PLS approach revealed that only the joint biomarker based on the top 2,3 or 4 genes is significant
The joint biomarker involving any number of the top 20 metabolites was significant
